Department of Medical Oncology, Institut de Cancérologie Nantes Atlantique CRLCC René Gauducheau, Boulevard Jacques Monod, Nantes Cedex/Saint-Herblain, France.
J Surg Oncol. 2011 Jan 1;103(1):10-6. doi: 10.1002/jso.21732.
The feasibility and safety of oxaliplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) associated with cytoreductive surgery (CRS) was assessed in patients with peritoneal carcinomatosis resulting from primary advanced or relapsing epithelial ovarian cancer (EOC).
Thirty-one patients received neoadjuvant platin-based chemotherapy followed by oxaliplatin-based HIPEC associated with CRS as consolidation of primary therapy (n = 19) or for relapsing disease (n = 12). Grade 3/4 complications were recorded according to National Cancer Institute definitions.
Median peritoneal carcinomatosis index (PCI) was 2.7 after neoadjuvant chemotherapy. Mean duration of surgery was 352 min (range 105-614) and median hospital stay was 11 days (range 6-87). Grade 3 toxicity was observed in nine patients: five required repeat surgery, two an invasive procedure, four rehospitalization, and three a return to the ICU. No grade 4 toxicity occurred, excepted one hypokalemia. Median progression-free survival (PFS) for primary advanced EOC was 13.2 months and 1-year PFS was 59.3%. Median PFS for relapsing patients was 14.3 months and 1-year PFS was 54.4%.
CRS with oxaliplatin-based HIPEC is feasible and relatively safe in recurrent and primary EOC. HIPEC after neoadjuvant chemotherapy reduces the PCI and decreases the number of surgical procedures and morbidity. Further evaluations of this procedure are required to assess the survival benefits.
评估奥沙利铂为基础的腹腔热灌注化疗（HIPEC）联合细胞减灭术（CRS）在原发性晚期或复发性上皮性卵巢癌（EOC）引起的腹膜癌病患者中的可行性和安全性。
31 名患者接受新辅助铂类化疗，然后接受奥沙利铂为基础的 HIPEC 联合 CRS，作为原发性治疗的巩固（n=19）或复发性疾病（n=12）的巩固治疗。根据国家癌症研究所的定义记录 3/4 级并发症。
新辅助化疗后中位腹膜癌病指数（PCI）为 2.7。手术平均持续时间为 352 分钟（范围 105-614 分钟），中位住院时间为 11 天（范围 6-87 天）。9 名患者出现 3/4 级毒性：5 名需要再次手术，2 名需要侵袭性操作，4 名需要重新住院，3 名需要返回 ICU。除 1 例低钾血症外，无 4 级毒性。原发性晚期 EOC 的中位无进展生存期（PFS）为 13.2 个月，1 年 PFS 为 59.3%。复发性患者的中位 PFS 为 14.3 个月，1 年 PFS 为 54.4%。
在复发性和原发性 EOC 中，CRS 联合奥沙利铂为基础的 HIPEC 是可行的，相对安全的。新辅助化疗后的 HIPEC 降低了 PCI，减少了手术次数和发病率。需要进一步评估该程序以评估其生存获益。
